Trevi Therapeutics (TRVI) Capital Expenditures (2018 - 2026)
Trevi Therapeutics' quarterly Capital Expenditures came in at $102000.0 in Q1 2026, up 750.0% quarter-over-quarter from $12000.0 in Q3 2025.
Trevi Therapeutics has reported Capital Expenditures for 8 years, with the latest figure at $102000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures changed N/A year-over-year to $102000.0; the trailing twelve-month figure through Mar 2026 stood at $121000.0 (changed N/A YoY), and the FY2025 full-year result was $12000.0, down 65.71% from the prior year.
- Capital Expenditures for Q1 2026 stood at $102000.0, up from $12000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $116000.0 in Q4 2022, with the low at $7000.0 in Q4 2024.
- Average Capital Expenditures over 5 years is $46750.0, with a median of $31000.0 recorded in 2023.
- Year-over-year, Capital Expenditures plunged 81.03% in 2023 and slumped 68.18% in 2024.
- Tracing TRVI's Capital Expenditures over 5 years: stood at $116000.0 in 2022, then sank by 81.03% to $22000.0 in 2023, then slumped by 68.18% to $7000.0 in 2024, then surged by 71.43% to $12000.0 in 2025, then jumped by 750.0% to $102000.0 in 2026.
- The last three Capital Expenditures figures came in at $102000.0 (Q1 2026), $12000.0 (Q3 2025), and $7000.0 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | 102,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102,000.00 |
| Mar 31, 2026 | 102,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Dec 31, 2023 | 22,000.00 |
| Dec 31, 2023 | 22,000.00 |
| Sep 30, 2023 | 18,000.00 |
| Sep 30, 2023 | 18,000.00 |
| Jun 30, 2023 | 40,000.00 |
| Jun 30, 2023 | 40,000.00 |
| Mar 31, 2023 | 57,000.00 |
| Mar 31, 2023 | 57,000.00 |
| Dec 31, 2022 | 116,000.00 |
| Dec 31, 2022 | 116,000.00 |
| Dec 31, 2020 | 5,000.00 |
| Dec 31, 2020 | 5,000.00 |
| Sep 30, 2020 | 15,000.00 |
| Sep 30, 2020 | 15,000.00 |
| Mar 31, 2019 | 9,000.00 |
| Mar 31, 2019 | 9,000.00 |
| Dec 31, 2018 | 92,000.00 |
| Dec 31, 2018 | 92,000.00 |
| Sep 30, 2018 | -1,000.00 |
| Sep 30, 2018 | -1,000.00 |
| Jun 30, 2018 | 10,000.00 |
| Jun 30, 2018 | 10,000.00 |
| Mar 31, 2018 | 57,000.00 |
| Mar 31, 2018 | 57,000.00 |